Drugs / Sodium Benzoate
Sodium Benzoate
also known as
Amzoate · Antimol · DAOIB · E-211 · FEMA NO. 3025 · Fuminaru · INS NO.211 · INS-211 · +7 more
Small molecule targets DAO via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | UCEPHAN | — | 1987-12-23 | fda.gov ↗ |
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05906303 | Dec 2023 → Dec 2024 | — | The Reading Hospital and Medical Center | Unknown | No outcome recorded |
| Phase 28 trials · 1 met primary | ||||||
| Phase 2 | NCT05006781 | Jan 2027 → Dec 2028 | dementia | Chang Gung Memorial Hospital | Suspended | No outcome recorded |
| Phase 2 | NCT04736355 | Jan 2020 → Jun 2024 | cognitive impairment with or without cerebellar ataxia | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03414931 | Jan 2016 → Nov 2020 | major depressive disorder | Chang Gung Memorial Hospital | Completed | Mixed |
| Phase 2 | NCT03752463 | May 2015 → Jul 2021 | Alzheimer disease | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02026947 | Feb 2014 → Dec 2016 | psychiatric disorder | Niuvanniemi Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT02103673 | Feb 2014 → Nov 2017 | brain small vessel disease 4 | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00960219 | Apr 2009 → Jul 2011 | schizophrenia | China Medical University Hospital | Completed | Met primary |
| Phase 2 | NCT00004767 | Jan 1985 → ? | inborn disorder of amino acid metabolism | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04022941 | Apr 2017 → Dec 2018 | liver disorder | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT06340789 Comparator | Nov 2021 → Apr 2028 expected | schizoaffective disorder, schizophrenia | National Cheng-Kung University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT03510741 Comparator | Jan 2019 → Dec 2020 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| — | NCT02111200 Comparator | Sep 2014 → Oct 2015 | urea cycle disorder | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sodium benzoate | “Previous studies showed that 750-mg/day or 1000-mg/day (but not 500-mg/day) sodium benzoate treatment improved cognitive function in AD patients with excellent safety and that...” PMID 40764372 ↗ Aug 202511“sodium benzoate, a D-amino acid oxidase inhibitor, improved short-term memory in patients with mild cognitive impairment” PMID 40405827 ↗ May 2025 “The Dose Finding Study of Sodium Benzoate Added to tDCS for the Treatment of Early-phase Alzheimer's Disease” NCT05006781 ↗ “sodium benzoate (a D-amino acid oxidase inhibitor and an indirect N-methyl-D-aspartate receptor enhancer)” PMID 35023557 ↗ Aug 2022 “Sodium benzoate is a d-amino acid oxidase inhibitor.” PMID 24089054 ↗ Dec 2013 |
| Known as | Amzoate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | Antimol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | DAOIB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02103673 ↗ |
| Known as | E-211 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | FEMA NO. 3025 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | Fuminaru | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | INS NO.211 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | INS-211 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | Microcare sb | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | Mthwsh | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | NaB | “Sodium Benzoate (NaB) could have an additive with NAC to act on several pathophysiological mechanisms implicated in schizophrenia.” PMID 39144112 ↗ Feb 2024 |
| Known as | Purox s | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | Sobenate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | Sodium benzoate component of ammonul | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Known as | Sodium benzoate component of ucephan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1356 ↗ |
| Action | Inhibit | “Sodium benzoate is a d-amino acid oxidase inhibitor.” PMID 24089054 ↗ Dec 2013 |
| Modality | Small molecule | — CHEMBL1356 ↗ |
| Route | Intravenous | “intravenous sodium benzoate” NCT00004767 ↗ |
| Target | DAO | “D-amino acid oxidase [DAO] inhibitor” PMID 40405827 ↗ May 2025 |